Alzheimer's disease and vascular risk factors;Maladie d'Alzheimer et facteurs de risque vasculaire

Revue de Medecine Interne

Volumn 32, Issue SUPPL. 1, 2011, Pages

  Hanon, O ^a   Duron, E ^a  

^a INSERM   (France)

Author keywords

Alzheimer's disease; Dementia; Vascular risk factors

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; DEMENTIA; RISK FACTOR;

ALZHEIMER DISEASE; DIABETES MELLITUS; HUMANS; HYPERCHOLESTEROLEMIA; INTRACRANIAL ARTERIOSCLEROSIS; RISK FACTORS;

EID: 79956272203     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.03.004     Document Type: Article

References (65)

1. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
2. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154.
3. Yoshitake T., Kiyohara Y., Kato I., et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995, 45(6):1161-1168.
4. Launer L.J., Ross G.W., Petrovitch H., et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2000, 21:49-55.
5. Kivipelto M., Helkala E.L., Laakso M.P., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population-based study. BMJ 2001, 322:1447-1451.
6. Qiu C., Winblad B., Viitanen M., et al. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke 2003, 34:594-599.
7. Wu C., Zhou D., Wen C., Zhang L., Como P., Qiao Y. Relationship between blood pressure and Alzheimer's disease in Linxian County, China. Life Sci 2003, 72:1125-1133.
8. Yamada M., Kasagi F., Sasaki H., et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc 2003, 51:410-414.
9. Luchsinger J.A., Reitz C., Honig L.S., et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005, 65:545-551.
10. Freitag M.H., Peila R., Masaki K., et al. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke 2006, 37:33-37.
11. Morris M.C., Scherr P.A., Hebert L.E., et al. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001, 58:1640-1646.
12. Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhäger W.H., Babarskiene M.R., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
13. Tzourio C., Anderson C., Chapman N., Woodward M., Neal B., MacMahon S., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069-1075.
14. Skoog I., Lithell H., Hansson L., Elmfeldt D., Hofman A., Olofsson B., et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005, 18:1052-1059.
15. Peters R., Beckett N., Forette F., Tuomilehto J., Clarke R., Ritchie C., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008, 7:683-689.
16. Curb J.D., Rodriguez B.L., Abbott R.D., et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999, 52:971-975.
17. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51:1256-1262. Honolulu-Asia Aging Study.
18. Schnaider Beeri M., Goldbourt U., Silverman J.M., et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004, 63:1902-1907.
19. Ott A., Stolk R.P., van Harskamp F., et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
20. MacKnight C., Rockwood K., Awalt E., et al. Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002, 14:77-83.
21. Luchsinger J.A., Tang M.X., Stern Y., et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001, 154:635-641.
22. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metforminute. J Alzheimers Dis 2011 [Epub ahead of print].
23. Irie F., Fitzpatrick A.L., Lopez O.L., Kuller L.H., Peila R., Newman A.B., et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon 4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008, 65:89-93.
24. Knopman D., Boland L.L., Mosley T., et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42-48.
25. Luchsinger J.A., Reitz C., Patel B., et al. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007, 64:570-575.
26. Biessels G.J., Staekenborg S., Brunner E., et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5:64-74.
27. Yaffe K., Blackwell T., Whitmer R.A., et al. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 2006, 10:293-295.
28. Ryan C.M., Freed M.I., Rood J.A., Cobitz A.R., Waterhouse B.R., Strachan M.W. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006, 29:345-351.
29. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
30. Williamson J.D., Miller M.E., Bryan R.N., Lazar R.M., Coker L.H., Johnson J., et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 2007, 99:112i-122i.
31. Cukierman-Yaffe T., Gerstein H.C., Williamson J.D., Lazar R.M., Lovato L., Miller M.E., et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009, 32:221-226.
32. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005, 13:950-958.
33. Erkinjuntti T. Vascular cognitive deterioration and stroke. Cerebrovasc Dis. 2007;24(Suppl 1):189-94.
34. Panza F., D'Introno A., Colacicco A.M., et al. Lipid metabolism in cognitive decline and dementia. Brain Res Rev 2006, 51:275-292.
35. Morley J.E., Banks W.A. Lipids and cognition. J Alzheimers Dis 2010, 20(3):737-747.
36. Notkola I.L., Sulkava R., Pekkanen J., et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998, 17:14-20.
37. Kivipelto M., Helkala E.L., Laakso M.P., et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002, 137:149-155.
38. Moroney J.T., Tang M.X., Berglund L., et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999, 282:254-260.
39. Kalmijn S., Foley D., White L., et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol 2000, 20:2255-2260.
40. Tan Z.S., Seshadri S., Beiser A., et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003, 163:1053-1057.
41. Reitz C., Tang M.X., Luchsinger J., Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004, 61:705-714.
42. Mielke M.M., Zandi P.P., Sjogren M., et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005, 64:1689-1695.
43. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009, 28:75-80.
44. Mielke M.M., Zandi P.P., Shao H., Waern M., Östling S., Guo X., et al. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 2010, 75:1888-1895.
45. Anstey K.J., Lipnicki D.M., Low L.F. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008, 16:343-354.
46. Raffaitin C., Gin H., Empana J.P., Helmer C., Berr C., Tzourio C., et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009, 32:169-174.
47. Reitz C., Tang M.X., Manly J., Schupf N., Mayeux R., Luchsinger J.A. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 2008, 25:232-237.
48. Reitz C., Tang M.X., Schupf N., Manly J.J., Mayeux R., Luchsinger J.A. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol 2010, 67:835-841.
49. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:23-33.
50. Shepherd J., Blauw G.J., Murphy M.B., et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
51. Feldman H.H., Doody R.S., Kivipelto M., Sparks D.L., Waters D.D., Jones R.W., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74:956-964.
52. McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R., Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010, 8:CD007514.
53. Pasquier F., Leys D. Why are stroke patients prone to develop dementia?. J Neurol 1997, 244:135-142.
54. de Leeuw F.E., Richard F., de Groot J.C., van Duijn C.M., Hofman A., Van Gijn J., et al. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004, 35:1057-1060.
55. Perlmutter L.S., Barron E., Saperia D., Chui H.C. Association between vascular basement membrane components and the lesions of Alzheimer's disease. J Neurosci Res 1991, 30:673-681.
56. Strandgaard S., Paulson O.B. Cerebrovascular consequences of hypertension. Lancet 1994, 344:519-520.
57. Yaffe K., Kanaya A., Lindquist K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237-2242.
58. Kumari M., Brunner E., Fuhrer R. Minireview: mechanisms by which the metabolic syndrome and diabetes impair memory. J Gerontol A Biol Sci Med Sci 2000, 55:B228-B232.
59. Qiu W.Q., Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006, 27:190-198.
60. Simons M., Keller P., De Strooper B., et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998, 95:6460-6464.
61. Bodovitz S., Klein W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996, 271:4436-4440.
62. Trompet S., de Craen A.J., Slagboom P., Shepherd J., Blauw G.J., Murphy M.B., et al. Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain 2008, 131:1069-1077.
63. Koudinov A.R., Koudinova N.V. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 2001, 15:1858-1860.
64. Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265(24):3255-3264.
65. Forette F., Seux M.L., Staessen J.A., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002, 162(18):2046-2052.